Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.85
Bid: 1.80
Ask: 1.90
Change: -0.20 (-9.76%)
Spread: 0.10 (5.556%)
Open: 2.05
High: 2.05
Low: 1.85
Prev. Close: 2.05
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Mar 2021 12:23

RNS Number : 2140T
Shield Therapeutics PLC
23 March 2021
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Shield Therapeutics Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Jupiter Fund Management Plc

City and country of registered office (if applicable)

 

4. Full name of shareholder(s) (if different from 3.)v

Name

Northern Trust

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

19/03/2021

6. Date on which issuer notified (DD/MM/YYYY):

23/03/2021

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuervii

Resulting situation on the date on which threshold was crossed or reached

5.87%

0%

5.87%

215,837,965

Position of previous notification (if

applicable)

N/A

N/A

N/A

N/A

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYV81293

N/A

12,679,400

N/A

5.87%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

12,679,400

5.87%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Jupiter Fund Management Plc

 

 

 

Jupiter Fund Management Group Limited

 

 

 

Jupiter Asset Management Group Limited

 

 

 

Knightsbridge Asset Management Limited

 

 

 

Jupiter Investment Management Group Limited

 

 

 

Jupiter Asset Management Limited

5.87%

 

5.87%

 

 

 

 

Jupiter Fund Management Plc

 

 

 

Merian Global Investors Limited

 

 

 

Merian Global Investors (Jersey) Limited

 

 

 

Merian Global Investors (Finance) Limited

 

 

 

Merian Global Investors Holdings Limited

 

 

 

Jupiter Investment Management Limited

 

 

 

     

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

 

 

11. Additional informationxvi

 

Contact : Jon Watson

 

Telephone Number : 0203 817 1672

 

 

 

 

 

Place of completion

London, UK

Date of completion

23rd March 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLJJMTTMTTTBBB
Date   Source Headline
26th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
25th May 20234:44 pmRNSPublication and posting of Offer Document
25th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
24th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
23rd May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
22nd May 20231:25 pmRNSForm 8.3 - Shield Therapeutics PLC
19th May 20234:17 pmRNSForm 8.3 - Shield Therapeutics Plc
19th May 20232:29 pmRNSForm 8.3 – Shield Therapeutics plc
19th May 20237:00 amRNS2022 Annual Report and 2023 AGM Notice
18th May 20233:15 pmRNSForm 8 (OPD) - Shield Therapeutics plc
18th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
17th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
17th May 20237:15 amEQSHardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions
16th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
12th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
11th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
10th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
9th May 20235:20 pmRNSForm 8 (OPD) - Shield Therapeutics plc
9th May 20234:00 pmRNSRule 2.9 Announcement and TVR Update
9th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
9th May 202311:04 amGNWForm 8.3 - Shield Therapeutics plc
5th May 20233:09 pmRNSForm 8 (DD) - Shield Therapeutics Plc
5th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
5th May 202311:55 amRNSForm 8.3 - SHIELD THERAPEUTICS PLC
4th May 20232:40 pmRNSAOP Loan Conversion and Mandatory Cash Offer
27th Apr 20237:00 amRNSBusiness Update and Unaudited Results
12th Apr 20237:00 amRNSNotice of Results
5th Apr 20237:00 amRNSAppointment of Chief Commercial Officer
31st Mar 20237:00 amRNSBlock Listing 6 Monthly Return
15th Mar 20234:35 pmRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSTotal Voting Rights Update
17th Feb 202311:05 amRNSSecond Price Monitoring Extn
17th Feb 202311:00 amRNSPrice Monitoring Extension
9th Feb 20234:40 pmRNSSecond Price Monitoring Extn
9th Feb 20234:35 pmRNSPrice Monitoring Extension
9th Feb 20239:05 amRNSSecond Price Monitoring Extn
9th Feb 20239:00 amRNSPrice Monitoring Extension
9th Feb 20237:00 amRNSFull Year Trading Update
23rd Jan 202311:15 amEQSHardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital
13th Jan 202310:30 amRNSHolding(s) in Company
13th Jan 20237:16 amEQSHardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability
12th Jan 20232:40 pmRNSHolding(s) in Company
12th Jan 20232:15 pmRNSHolding(s) in Company
9th Jan 20235:10 pmRNSPartial AOP Loan Conversion
9th Jan 20233:56 pmRNSHolding(s) in Company
9th Jan 20233:25 pmRNSHolding(s) in Company
5th Jan 20233:45 pmRNSResult of General Meeting & Open Offer
28th Dec 20227:00 amRNSTotal Voting Rights Update
28th Dec 20227:00 amRNSPDMR Transaction Notification
16th Dec 20227:00 amRNSPublication of Circular &Notice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.